Grants and Contributions

This project supports the hiring of two recent graduates to expand the company’s development team. The new hires will contribute to advancing the organization’s R&D roadmap by supporting software development, testing, and implementation activities. Their work will enhance internal capacity, accelerate innovation, and help bring new features and improvements to market more efficiently. This initiative supports both talent development and the company’s long-term growth objectives.

This project will develop a frontier laser welding technology to enable the low-cost, high-volume manufacturing of advanced polymer microfluidic devices in Canada, fostering domestic job creation and supply chain resilience.

ChocoSol proposes to hire a recent graduate as a Marketing & E-Commerce Associate. In this role it is critical to implementing a transformative digital strategy in collaboration with TradeTools, a leading Toronto marketing consultancy, and integrating third-party logistics (3PL) with eShipper. The project aims to enhance ChocoSol's online presence, optimize customer journeys, streamline fulfillment processes, and align in-person and digital brand experiences, ultimately contributing to the company's growth and mission.

During the project, Clinisys intends to integrate and test mature Generative AI tools such as scribe via API integration to AI-enable the firm's flagship product – Clinisys EMR. The firm will develop AI scribe specific interfaces that would allow relevant voice data through this interface to be transcribed using AI into text. The intended users will be physicians and clinicians using the system that would allow recording of patient interviews and population of relevant patient encounter fields from within Clinisys EMR interface. This will shorten the time of encounter where currently either the physicians must type the notes or use pre-configured patient encounter templates.

The project will develop an MVP open B2B platform that will enable small ISPs to offer emerging services beyond basic connectivity. The platform integrates affordable Operational and Billing Support Systems with advanced security and trust infrastructure, allowing independents to deliver a suite of services including healthcare monitoring, elder protection, and smart home services typically reserved for large carriers. The MVP will begin with a demo on how integrated spectrum management, smart gateways, and unified business systems can enable small ISPs to compete through service innovation.

As part of the international consortium project “UK Multisector – BioM - LV Production Kit: Development of GMP lentiviral production kit with optimized upstream and downstream processes” this project will develop an end-to-end and off-the-shelf GMP enabled lentivirus manufacturing kit. The current standard in lentivirus manufacturing is inefficient and delivers low yields, leading to elevated manufacturing costs and less accessible therapeutics. This kit will be the first of its kind, integrating innovative upstream and downstream technologies that have been demonstrated to significantly enhance both upstream manufacturing yields and downstream processing recovery and contributing to the greater accessibility of ex-vivo gene therapy.

YEP support to hire a recent engineering graduate to support Exhilarare's development of a novel, scalable material manufacturing process.

Airdrop has the potential to expand the reach of autonomous aircraft delivering time-critical cargo. However, autonomous airdrop requires advanced navigation and control systems to deliver goods safely and accurately. In this project, Ribbit is developing airdrop navigation and control software that delivers new capabilities on top of its existing autonomous stack.

The project will test AI strategies for agricultural crops.

This project aims to develop and validate a novel platform for laser-assisted targeted drug delivery using LMI's proprietary picosecond mid-infrared laser technology. This technology enables precise ablation of tissues and when coupled to a microfluidic drug channel, the optic probe can deliver localized therapeutics with high resolution and minimal invasiveness. LMI holds foundational IP specific to this application covering fiberoptic laser-drug delivery systems in addition to the original core IP portfolio covering the unique laser tissue interaction. The platform will be validated in, phantom tissue, ex vivo and animal models, focusing on applications in high-value organ systems: prostate, brain, lung, and pancreas.